الفهرس 
Design and evaluation of certain oral mucoadhesive nano-drug delivery systems
contentsOnly 14 pages are availabe for public view
 |  | from | 162 |  |  |
| | | from | 162 | | |
Abstract
Oral cancer is a global health problem with increased incidence and high rate of recurrence and metastasis.There are different protocols for treatment of cancers of the oral cavity including surgery, radiotherapy, and, the most frequently applied approach, chemotherapy. However, chemotherapy results in severe adverse effects such as nausea, vomiting, constipation, diarrhea, fatigue, hair loss, and mucositis. Cyclooxegenase-2 (COX-2) enzyme is over expressed in oral cancer cells and affects a number of carcinogenesis processes. The inhibition of COX-2 enzyme could be an intriguing remedial target. Celecoxib (CXB), a selective COX-2 inhibitor, is considered an effective chemopreventive therapeutic target for oral carcinoma. Unfortunately, its clinical application is vulnerable due to its poor aqueous solubility and hence, low absorption and bioavailability. In addition, the systemic side effects of CXB would further limit its potential. For these reasons, encapsulating CXB in nano-drug delivery systems could offer a promising strategy to circumvent these drawbacks. Additionally, loading the prepared nanocarrier on a mucoadhesive polymer would further enhance the localized delivery of CXB by increasing its intimate contact with the buccal mucosa. Hence, this would increase the drug tissue accumulation and avoid the systemic side effects associated with high dosing. The aim of the present work is to formulate and evaluate oral mucoadhesive nano-drug delivery systems of CXB for localized treatment of oral carcinoma with minimized drug dosing and reduced associated systemic adverse effects